Targeting innate sensing in the tumor microenvironment to improve immunotherapy (Q92024962)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

26 April 2020

review article

1 reference

title

Targeting innate sensing in the tumor microenvironment to improve immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

26 April 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

26 April 2020

author name string

Zhida Liu

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

26 April 2020

Chuanhui Han

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

26 April 2020

publication date

16 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

Cellular and Molecular Immunology

26 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

26 April 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

26 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

26 April 2020

page(s)

13-26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31844141 AND SRC:MED&resulttype=core&format=json

Approaching the asymptote? Evolution and revolution in immunology

26 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Toll-like receptor control of the adaptive immune responses

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Toll-like receptors: linking innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Toll-like receptors and cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cancer immunoediting: from immunosurveillance to tumor escape

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Innate immune signaling and regulation in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Tumor-infiltrating CD8 lymphocytes predict clinical outcome in breast cancer.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immune infiltration in human tumors: a prognostic factor that should not be ignored

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Assessment of the evolution of cancer treatment therapies

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Targeted Cancer Therapy: The Next Generation of Cancer Treatment

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

An overview of targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Biological response of cancer cells to radiation treatment

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Universes collide: combining immunotherapy with targeted therapy for cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immunotherapy and tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Prospects for combining targeted and conventional cancer therapy with immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Combining targeted therapy with immunotherapy. Can 1 1 equal more than 2?

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Toll-like receptors: how they work and what they do.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Toll-like receptor signaling pathways

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The Toll-IL-1 receptor adaptor family grows to five members.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Recognition and signaling by toll-like receptors.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Toll-like receptors and innate immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Mechanisms and pathways of innate immune activation and regulation in health and cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

TLR signaling by tumor and immune cells: a double-edged sword

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The Role of Toll-Like Receptor in Inflammation and Tumor Immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Anti-tumor Activity of Toll-Like Receptor 7 Agonists

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

From the analyst's couch: TLR-targeted therapeutics

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Flagellin increases death receptor-mediated cell death in a RIP1-dependent manner

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

C-type lectins in immunity: recent developments

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The C-type lectin-like domain superfamily

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

C-type lectin receptors orchestrate antifungal immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Signaling by myeloid C-type lectin receptors in immunity and homeostasis

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Syk-coupled C-type lectins in immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Flexible Signaling of Myeloid C-Type Lectin Receptors in Immunity and Inflammation.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Signalling C-type lectins in antimicrobial immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Inhibitory C-type lectin receptors in myeloid cells

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Signalling through C-type lectin receptors: shaping immune responses

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Recognition of tumor glycans by antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The role of C-type lectin receptors in immune homeostasis

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Tumor-associated macrophages: from mechanisms to therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Targeting antigens to dendritic cells in vivo

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Intracellular pattern recognition receptors in the host response

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Regulation of the antimicrobial response by NLR proteins.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

NOD-Like Receptors: Master Regulators of Inflammation and Cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

NOD-like receptors: role in innate immunity and inflammatory disease

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Sensing and reacting to microbes through the inflammasomes

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Pyroptosis: host cell death and inflammation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Gout-associated uric acid crystals activate the NALP3 inflammasome

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Nod-like receptors in head and neck squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The NLRP3 inflammasome, a target for therapy in diverse disease states

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immune sensing of DNA

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Viral RNA detection by RIG-I-like receptors

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

DNA-PK is a DNA sensor for IRF-3-dependent innate immunity.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Master sensors of pathogenic RNA - RIG-I like receptors

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8( ) T cells

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Dose dependent activation of retinoic acid-inducible gene-I promotes both proliferation and apoptosis signals in human head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Interferons, interferon-like cytokines, and their receptors

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Type I interferon response and innate immune sensing of cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cytosolic surveillance and antiviral immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Mechanisms of type-I- and type-II-interferon-mediated signalling

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Direct effects of type I interferons on cells of the immune system

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Type I IFNs control antigen retention and survival of CD8α( ) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Interferons, immunity and cancer immunoediting

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

A critical function for type I interferons in cancer immunoediting

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Host type I IFN signals are required for antitumor CD8 T cell responses through CD8{alpha} dendritic cells

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cancer and radiation therapy: current advances and future directions

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Protons and more: state of the art in radiotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

ROS and the DNA damage response in cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Therapeutic effects of ablative radiation on local tumor require CD8 T cells: changing strategies for cancer treatment

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immunogenic cell death and DAMPs in cancer therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Mitotic progression following DNA damage enables pattern recognition within micronuclei.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

cGAS surveillance of micronuclei links genome instability to innate immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

cGAS Conducts Micronuclei DNA Surveillance

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

IFI16 protein mediates the anti-inflammatory actions of the type-I interferons through suppression of activation of caspase-1 by inflammasomes

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Type I interferon signaling is required for activation of the inflammasome during Francisella infection

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Inflammasome Activation Triggers Caspase-1-Mediated Cleavage of cGAS to Regulate Responses to DNA Virus Infection

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Gasdermin D Restrains Type I Interferon Response to Cytosolic DNA by Disrupting Ionic Homeostasis

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

UV light and ionizing radiations cause programmed death of rat chloroleukaemia cells by inducing retropositions of a mobile DNA element (L1Rn).

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Regulation of ferroptotic cancer cell death by GPX4

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Ferroptosis: an iron-dependent form of nonapoptotic cell death

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

CD8 T cells regulate tumour ferroptosis during cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immunogenic cell death in cancer therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immunogenic cell death in cancer therapy: Present and emerging inducers

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Mechanism of action of anti-HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Anti-CD20 antibody therapy for B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

CTLA-4 Limits Anti-CD20-Mediated Tumor Regression

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

CD47 blockade triggers T cell-mediated destruction of immunogenic tumors

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Protein kinases as drug targets in cancer.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Effective combinatorial immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

PARP inhibitors: Synthetic lethality in the clinic

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

PARP Inhibitor Efficacy Depends on CD8 T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The requirement for cyclin D function in tumor maintenance

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

CDK4/6 inhibition triggers anti-tumour immunity.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Therapeutic cancer vaccines: past, present, and future

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cytokines in clinical cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Adapting conventional cancer treatment for immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Adenine Nucleotides Attenuate Murine T Cell Activation Induced by Concanavalin A or T Cell Receptor Stimulation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Radiotherapy promotes tumor-specific effector CD8 T cells via dendritic cell activation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

NKG2D and its ligands in cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Cytokines in radiobiological responses: a review

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

PD-1 Restrains Radiotherapy-Induced Abscopal Effect.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Enhancing CAR T-cell therapy through cellular imaging and radiotherapy

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Magnitude of Therapeutic STING Activation Determines CD8 T Cell-Mediated Anti-tumor Immunity

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

CBLB613: A TLR 2/6 Agonist, Natural Lipopeptide ofMycoplasma arginini, as a Novel Radiation Countermeasure

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Administration of cyclophosphamide changes the immune profile of tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Metronomic cyclophosphamide regimen selectively depletes CD4 CD25 regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation.

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021

EGFR TKI combination with immunotherapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038/S41423-019-0341-Y

7 January 2021